Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of GS3-007a Oral Solution in Healthy Chinese Adults
NCT05921890Phase 1Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Jun 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GS3-007 in growth hormone deficiency (GHD) (3 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoint: Treatment-Emergent Adverse Events at 35 days. Started Jun 2023; status: completed.
02
Drugs
GS3-007
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT05921890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05921890.